Darolutamide with androgen deprivation therapy recommended for treating hormone-relapsed non-metastatic prostate cancer
People taking the combination treatment have more time before their prostate cancer spreads compared with androgen deprivation therapy alone, says NICE guidance.
Published
Join OnMedica and benefit from:
- Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
- High-quality, evidence-based content developed by expert editors and clinicians
- Articles, quizzes, videos, visual summaries and more
- Regulatory alerts and round-up of medical journals
- New content added daily, so you know you’re always up to date
No comments yet.